MELA Sciences is a medical device company focused on the design, development and commercialization of non-invasive tools to provide
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 1, 2015 | Post-IPO Debt | $10M | 1 | Hercules Capital | — | Detail |
Dec 1, 2014 | Post-IPO Debt | $20M | 1 | Hercules Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |